Literature DB >> 26352789

The management and prognosis of patients with hepatocellular carcinoma: what has changed in 20 years?

Sun Young Yim1, Yeon Seok Seo1, Chang Ho Jung1, Tae Hyung Kim1, Jae Min Lee1, Eun Sun Kim1, Bora Keum1, Young Kul Jong1, Hyunggin An2, Ji Hoon Kim1, Hyung Joon Yim1, Dong Sik Kim3, Yoon Tae Jeen1, Jong Eun Yeon1, Hong Sik Lee1, Hoon Jai Chun1, Kwan Soo Byun1, Soon Ho Um1, Chang Duck Kim1, Ho Sang Ryu1.   

Abstract

BACKGROUND & AIMS: There has been remarkable progress in the management of hepatocellular carcinoma (HCC) during the last several decades, but its effect on the prognosis of HCC patient needs clarification. We analysed the changes that affected prognosis of HCC patients diagnosed over two different eras.
METHODS: A retrospective study of 1318 patients diagnosed with HCC from 1986 to 2012 was conducted. Analysis was done according to two cohorts, cohort 1 (patients diagnosed with HCC from 1986 to 1992) and cohort 2 (patients diagnosed from 2006 to 2012).
RESULTS: Hepatitis B virus was the most common cause of liver disease for both cohorts (66.2% and 66.0%). The proportion of patients with Barcelona Clinic Liver Cancer stage 0/A was significantly lower in cohort 1 than in cohort 2 (14.4% vs. 39.5%, P < 0.001). The proportions of patients diagnosed during surveillance and general health check-up were significantly higher in cohort 2 than in cohort 1 (28.6% vs. 10.6% and 26.3% vs. 7.9%, respectively) while those diagnosed during symptomatic evaluation was significantly higher in cohort 1 than in cohort 2 (45.1 vs. 81.4%, P < 0.001). Surgical resection rate was similar between the two cohorts (26.1% vs 26%) while the transcatheter arterial chemoembolization rate which was the highest in cohort 1 (40.6%) was overtaken by radiofrequency ablation in cohort 2 (55%) at BCLC stage 0/A. Median survival duration in cohort 2 was significantly longer than cohort 1 (65.0 vs. 7.9 months, P < 0.001).
CONCLUSIONS: Implementation of national cancer surveillance and the advancement of treatment modalities have likely led to early detection of HCC and improvements in prognosis over the last 20 years.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  hepatitis B virus; hepatocellular carcinoma; radiofrequency ablation

Mesh:

Year:  2015        PMID: 26352789     DOI: 10.1111/liv.12960

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  8 in total

1.  Liver resection for early hepatocellular cancer: Comparison of centers in 3 different countries.

Authors:  Linda L Wong; Brenda Y Hernandez; Yurii B Shvetsov; Yoichi Kawano; Zhao-You Tang; Jun-Fang Ji
Journal:  World J Hepatol       Date:  2016-11-08

2.  Deciphering the epidemiology of hepatocellular carcinoma through the passage of time: A study of 1,401 patients across 3 decades.

Authors:  George Boon-Bee Goh; James Weiquan Li; Pik-Eu Chang; Khuan-Yew Chow; Chee-Kiat Tan
Journal:  Hepatol Commun       Date:  2017-06-14

3.  The impact of esophagogastric varices on the prognosis of patients with hepatocellular carcinoma.

Authors:  Wei-Yao Hsieh; Ping-Hsien Chen; I-Yen Lin; Chien-Wei Su; Yee- Chao; Teh-Ia Huo; Yi-Hsiang Huang; Ming-Chih Hou; Han-Chieh Lin; Jaw-Ching Wu
Journal:  Sci Rep       Date:  2017-02-17       Impact factor: 4.379

Review 4.  The epidemiology of hepatitis B virus infection in Korea.

Authors:  Sun Young Yim; Ji Hoon Kim
Journal:  Korean J Intern Med       Date:  2019-03-29       Impact factor: 2.884

5.  Comparison of 2 curative treatment options for very early hepatocellular carcinoma: Efficacy, recurrence pattern, and retreatment.

Authors:  Tae Hyung Kim; Jung Mi Chang; Soon Ho Um; Heejung Jee; Yoo Ra Lee; Han Ah Lee; Sun Young Yim; Na Yeon Han; Jae Min Lee; Hyuk Soon Choi; Eun Sun Kim; Young-Dong Yu; Bora Keum; Min Ju Kim; Hyunggin An; Beom Jin Park; Yeon Seok Seo; Dong-Sik Kim; Hyung Joon Yim; Sung Bum Cho; Yoon Tae Jeen; Hong Sik Lee; Hoon Jai Chun; Yun Hwan Kim; Chang Duck Kim
Journal:  Medicine (Baltimore)       Date:  2019-06       Impact factor: 1.817

6.  Survival in untreated hepatocellular carcinoma: A national cohort study.

Authors:  Young Ae Kim; Danbee Kang; Hyeyoung Moon; Donghyun Sinn; Minwoong Kang; Sang Myung Woo; Yoon Jung Chang; Boram Park; Sun-Young Kong; Eliseo Guallar; Soo-Yong Shin; Geunyeon Gwak; Joung Hwan Back; Eun Sook Lee; Juhee Cho
Journal:  PLoS One       Date:  2021-02-04       Impact factor: 3.240

7.  Impact of acute decompensation on the prognosis of patients with hepatocellular carcinoma.

Authors:  Takayuki Kondo; Keisuke Koroki; Hiroaki Kanzaki; Kazufumi Kobayashi; Soichiro Kiyono; Masato Nakamura; Naoya Kanogawa; Tomoko Saito; Sadahisa Ogasawara; Yoshihiko Ooka; Shingo Nakamoto; Tetsuhiro Chiba; Makoto Arai; Jun Kato; Satoshi Kuboki; Masayuki Ohtsuka; Naoya Kato
Journal:  PLoS One       Date:  2022-01-27       Impact factor: 3.240

8.  Long-term outcome of intraoperative radiofrequency ablation for hepatocellular carcinoma and its efficacy as a primary treatment.

Authors:  Jongduk Kwon; Kwang-Sik Chun; In-Sang Song; Seok-Hwan Kim; Sunjong Han
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2020-02-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.